Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | TYMP | P19971 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029299 | 1.00 | PKM (0.38) | PKMCYP2D6CYP3A4CYP2C19EPHX2 | |
| SCHEMBL13213232 | 1.00 | PKM (0.38) | PKMCYP2D6CYP3A4CYP2C19EPHX2 | |
| SCHEMBL1700411 | 0.88 | NR1H2 (0.33) | PKMCYP3A4CYP2C19 | |
| SCHEMBL1700787 | 0.88 | NR1H2 (0.33) | PKMCYP3A4CYP2C19 | |
| SCHEMBL624078 | 0.88 | NR1H2 (0.33) | PKMCYP3A4CYP2C19 | |
| SCHEMBL23916739 | 0.85 | CYP2D6 (0.35) | PKMCYP2D6CYP3A4CYP2C19EPHX2 | |
| SCHEMBL16019929 | 0.85 | AKR1C3 (0.36) | — | |
| SCHEMBL2658021 | 0.84 | CYP3A4 (0.33) | PKMCYP2D6CYP3A4CYP2C19EPHX2 | |
| SCHEMBL10274325 | 0.82 | CYP1A2 (0.31) | — | |
| SCHEMBL20381527 | 0.82 | CYP1A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210024505-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-01-28 | — | — | US | disclosed |
| US-20200347068-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190322650-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-24 | — | — | US | disclosed |
| CN-110300752-A | Monocycle OGA inhibitor compound | 詹森药业有限公司 | 2019-10-01 | — | — | CN | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-10 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | PKM 2798/4885CYP2D6 547/4885CYP3A4 1056/4885 |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | PKM 3378/4885CYP2D6 2034/4885CYP3A4 2231/4885 |
| US-20190322650-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | PKM 3413/4885CYP2D6 955/4885CYP3A4 1164/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | PKM 2981/4885CYP2D6 883/4885CYP3A4 1775/4885 |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | PKM 3330/4885CYP2D6 1127/4885CYP3A4 1368/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | PKM 230/4885CYP2D6 1015/4885CYP3A4 1629/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | PKM 3624/4885CYP2D6 1363/4885CYP3A4 1886/4885 |
| US-20210024505-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | PKM 3413/4885CYP2D6 955/4885CYP3A4 1164/4885 |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | PKM 3413/4885CYP2D6 955/4885CYP3A4 1164/4885 |
| US-20200347068-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | PKM 3378/4885CYP2D6 2034/4885CYP3A4 2231/4885 |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | PKM 3413/4885CYP2D6 955/4885CYP3A4 1164/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | PKM 3413/4885CYP2D6 955/4885CYP3A4 1164/4885 |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | CFTR, ABCB4, ABCF2 | PKM 1135/4885CYP2D6 1964/4885CYP3A4 1844/4885 |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | PKM 3414/4885CYP2D6 961/4885CYP3A4 1141/4885 |
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | DCK, PDK4, PDK2 | PKM 593/4885CYP2D6 2054/4885CYP3A4 2746/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | PKM 3673/4885CYP2D6 1404/4885CYP3A4 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.